Intranasal (IN) midazolam was equally effective and showed comparable safety for the treatment of acute pediatric seizure emergencies as compared to intravenous (IV) or rectal diazepam, according to ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable ...
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use ...
Acceptance of Investigational New Drug Application is another significant milestone in the effort to address the significant need for a therapy for acute repetitive seizures outside of the hospital ...
Lorazepam does not have better efficacy and safety than diazepam for pediatric status epilepticus, according to results of a head-to-head comparison. On the basis of the findings, "hospitals should ...
AUSTIN, Texas — For acute seizure emergencies in children, intranasal midazolam is as safe and effective as intravenously or rectally administered diazepam, according to a systematic review of ...
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual ...
SAN DIEGO, Jan. 13, 2020 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO ® (diazepam nasal spray) as an acute treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results